Loading…
PAVmed Inc. is projected to decline to $5.37 by 2027, a -4% move from its current price of $5.60. PAVM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $5.35 | $5.61 | $5.88 | +0.11% |
| Jul 15 | $5.25 | $5.61 | $6.00 | +0.21% |
| Jul 16 | $5.18 | $5.62 | $6.10 | +0.32% |
| Jul 17 | $5.12 | $5.62 | $6.18 | +0.43% |
| Jul 18 | $5.06 | $5.63 | $6.26 | +0.54% |
| Jul 19 | $5.02 | $5.64 | $6.33 | +0.65% |
| Jul 20 | $4.98 | $5.64 | $6.40 | +0.75% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.98 | $5.64 | $6.40 | +0.75% |
| Week 2 | $4.76 | $5.68 | $6.79 | +1.51% |
| Week 3 | $4.61 | $5.73 | $7.12 | +2.28% |
| Week 4 | $4.49 | $5.77 | $7.42 | +3.05% |
| Week 5 | $4.39 | $5.81 | $7.70 | +3.83% |
| Week 6 | $4.31 | $5.86 | $7.97 | +4.61% |
| Week 7 | $4.24 | $5.90 | $8.23 | +5.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PAVmed Inc. is a healthcare company focused on acquiring, developing, and commercializing novel products that target unmet needs in the United States. Its lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, a diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device.
The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed was incorporated in 2014 and is headquartered in New York, New York.
PAVmed Inc. (PAVM) is a healthcare stock currently trading at $5.25 per share with a market capitalization of $37.58M. Its market position is reflected by a rank of 4690. The price outlook is grounded in a multi-year forecast showing variation across years, with the average price projected to rise from $5.25 in 2026 to a long-run average of $21.36 by 2050, and a maximum forecast of $49.14 in 2050.
These projections imply meaningful upside over the extended horizon but are estimates, not guarantees.
A major floor 38.1% below — a decisive break under it would weaken the trend.
The nearest floor, 22.3% below — buyers have tended to step in here.
The nearest ceiling, 12.5% above — a clean break opens room to run.
A major ceiling 91.8% above — clearing it would confirm fresh momentum.
Key PAVM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PAVM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.42 | Buy | $5.51 | Buy |
| MA 10 | $5.55 | Buy | $5.44 | Buy |
| MA 20 | $5.20 | Buy | $5.44 | Buy |
| MA 50 | $6.00 | Sell | $6.14 | Sell |
| MA 100 | $7.87 | Sell | $7.35 | Sell |
| MA 200 | $9.32 | Sell | $10.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.81 | Neutral |
| Stoch RSI (14) | 72.48 | Neutral |
| CCI (20) | 73.97 | Neutral |
| Williams %R (14) | -35.90 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 19.66 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 64.10 | Neutral |
| TRIX (15) | -0.59 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 45.35 | Neutral |
| Momentum (10) | 1.25 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 5.37 | Buy |
| ADX (14) | 22.43 | Buy |
| ATR (14) | 0.25 | Info |
The near-term technical picture is NEUTRAL. The RSI14 is 50, indicating a balanced momentum reading. The stock trades relative to the moving averages, with a SMA50 of $6.19 and a SMA200 of $9.43. Support is identified at $4.35 and resistance at $6.39, framing a 30-day range of $3.75 to $7.35.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.35 | $5.60 | $8.14 | 0% | Neutral | |
| $3.98 | $5.37 | $7.81 | -4% | Neutral | |
| $5.06 | $7.19 | $11.07 | +28% | Bullish | |
| $5.76 | $8.56 | $13.78 | +53% | Bullish | |
| $5.33 | $8.25 | $13.78 | +47% | Bullish | |
| $4.95 | $7.95 | $13.71 | +42% | Bullish | |
| $4.55 | $7.56 | $13.43 | +35% | Bullish | |
| $4.43 | $7.62 | $13.88 | +36% | Bullish | |
| $4.27 | $7.59 | $14.14 | +35% | Bullish | |
| $5.12 | $9.41 | $17.91 | +68% | Bullish | |
| $4.35 | $9.31 | $19.35 | +66% | Bullish | |
| $10.40 | $23.11 | $53.15 | +313% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.35 | $5.60 | $6.80 | +0.00% |
| August 2026 | $5.00 | $6.02 | $7.52 | +7.45% |
| September 2026 | $5.07 | $6.18 | $7.87 | +2.63% |
| October 2026 | $4.76 | $5.86 | $7.59 | -5.04% |
| November 2026 | $4.73 | $5.88 | $7.70 | +0.25% |
| December 2026 | $4.90 | $6.14 | $8.14 | +4.46% |
Click any year to see its month-by-month PAVM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
PAVmed Inc.'s 2026 outlook centres on $5.60, within a $4.35 to $8.14 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, PAVM could reach as high as $7.81, with a base case around $5.37 and support toward $3.98 — roughly -4% from $5.60. Price action looks broadly range-bound.
Expect PAVM to range from $5.06 to $11.07 through 2028. The $7.19 average target implies a +28% move from current prices. That is up +34% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The PAVM price prediction for 2029 points to an average of $8.56 (low $5.76, high $13.78) — a potential gain of +53% on today's $5.60. Momentum favours further upside here.
In 2030, PAVM is projected to trade between $5.33 and $13.78, averaging $8.25 — a potential gain of +47% from today's $5.60. That is -4% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
PAVmed Inc.'s 2031 outlook centres on $7.95, within a $4.95 to $13.71 range. That is -4% versus the projected 2030 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2032, PAVM could reach as high as $13.43, with a base case around $7.56 and support toward $4.55 — roughly +35% from $5.60. Buyers look set to stay in control over this stretch.
Expect PAVM to range from $4.43 to $13.88 through 2033. The $7.62 average target implies a +36% move from current prices. That is up +1% on the projected 2032 average. Momentum favours further upside here.
The PAVM price prediction for 2034 points to an average of $7.59 (low $4.27, high $14.14) — a potential gain of +35% on today's $5.60. Buyers look set to stay in control over this stretch.
In 2035, PAVM is projected to trade between $5.12 and $17.91, averaging $9.41 — a potential gain of +68% from today's $5.60. That is up +24% on the projected 2034 average. Momentum favours further upside here.
PAVmed Inc.'s 2040 outlook centres on $9.31, within a $4.35 to $19.35 range. That is -1% versus the projected 2035 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, PAVM could reach as high as $53.15, with a base case around $23.11 and support toward $10.40 — roughly +313% from $5.60. Momentum favours further upside here.
Investing $1,000 in PAVM today (≈ 178.571429 PAVM) could be worth
$4,126.32
+$3,126.32 (+313%) by 2050 · US Dollar
Based on the average projected PAVM price of $23.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PAVMwould be worth at today's price.
$1,000 invested in PAVM on Jul 10, 2025 (≈ 55.555556 PAVM) would be worth
$311.11
-$688.89 (-68.9%) today · 0.31× · US Dollar
Based on a PAVM entry price of $18 vs. today's $5.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.71 | $980.74 | -1.9% |
| 1 month ago | $4.98 | $1,124.5 | +12.4% |
| 3 months ago | $9.24 | $606.06 | -39.4% |
| 6 months ago | $8.13 | $688.81 | -31.1% |
| 1 year ago | $18 | $311.11 | -68.9% |
| All time (5.0y) ago | $2,380.5 | $2.35 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PAVM forecast.
Our base-case forecast reaches $11.00 around 2050.
Implied market cap at $11.00: $78.75M
The multi-year forecast shows a bullish trajectory across the coming years. In 2026 the min price is $4.35, the avg is $5.25, and the max is $7.75, with a 0% ROI. In 2027 the min is $3.56, the avg $4.87, the max $7.20, with a -7.2% ROI.
From 2028 onward the outlook improves: the 2028 avg is $6.72 (28.1% ROI), 2029 avg $8.08 (53.9% ROI), and 2030 avg $7.67 (46.1% ROI). The forecast continues with 2031 avg $7.49 (42.6% ROI), 2032 avg $7.04 (34.2% ROI), 2033 avg $6.94 (32.1% ROI), and 2034 avg $6.93 (31.9% ROI). By 2035 the avg rises to $8.62 (64.3% ROI), and the path remains bullish through 2040 with an avg of $8.49 (61.6% ROI).
The long-run projection for 2050 shows an avg of $21.36 with a max of $49.14, delivering a 306.9% ROI. These figures are estimates and reflect potential upside with associated uncertainty.
Tap a question to reveal the answer.
Avg $7.67; min $4.82; max $13.12; ROI 46.1%; sentiment BULLISH.
Forecasts show a mix of outcomes: 2026 min $4.35, avg $5.25, max $7.75 (ROI 0%); 2027 min $3.56, avg $4.87, max $7.20 (ROI -7.2%); 2028 avg $6.72 (ROI 28.1%); 2029 avg $8.08 (ROI 53.9%); 2050 avg $21.36 (ROI 306.9%). The long-run view is bullish, but these are estimates and not guarantees.
Yes—the 2030 forecast max is $13.12, with a 2030 avg of $7.67, so reaching above $10 is within the upper forecast bound, though these are estimates.
Current price is $5.25 and market cap is $37.58M.
Sentiment: NEUTRAL. RSI14 is 50. SMA50 is $6.19 and SMA200 is $9.43. Support is at $4.35 and resistance at $6.39. The 30-day price range is $3.75 to $7.35.
PAVmed Inc. Community Discussion
0Share your PAVmed Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.